Perillyl Alcohol in Treating Patients With Refractory Cancer

• Status: Completed
• Trial end date: 1969-12-31
• Target enrollment: 0
• Participant gender: All

Summary

Phase I trial to study the effectiveness of perillyl alcohol in treating patients with refractory cancer. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die.

• Phase: Phase 1
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: National Cancer Institute (NCI)
• Treatments: Ethanol; Perilla alcohol; Perillyl alcohol

Criteria

DISEASE CHARACTERISTICS:

• Histologically confirmed solid malignancy or lymphoma for which no effective therapy exists

• Measurable or evaluable disease

• No CNS metastasis unless stable for at least 4 weeks following surgery and/or radiotherapy and no requirement for anticonvulsants

PATIENT CHARACTERISTICS:

• Age: Over 18

• Performance status: ECOG 0-2

• Life expectancy: At least 3 months

• ANC at least 1,500

• Platelets at least 100,000

• Bilirubin no greater than 2.0 mg/dL

• AST less than 2.5 times normal

• Creatinine clearance at least 50 mL/min

• No concurrent cholesterol-lowering agents

• No active infection (including HIV)

• No concomitant medical condition that precludes study compliance

• No pregnant or nursing women

• Adequate contraception required of fertile patients

PRIOR CONCURRENT THERAPY:

• At least 4 weeks since chemotherapy (6 weeks since nitrosoureas or mitomycin)

• At least 4 weeks since wide-field radiotherapy

• Fully recovered from prior surgery